reports
1 director bought
A director at Tenax Therapeutics Inc bought 6,425 shares at 5.420USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
Tenax Therapeutics Announces Results of Pre-IND Meeting with FDA for P...
MORRISVILLE, N.C.--(BUSINESS WIRE)-- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on providing products to address conditions with significant unmet medical needs, today announced the results of its pre-Investigational New Drug (pre-IND) meeting with the United States Food & Drug Administration (FDA), where the FDA addressed the Company’s questions and provided guidance on its upcoming Phase 2 clinical trial in the use of levosimendan for treatment of Pulmonary Hypertension associated with Heart ...
Tenax Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Re...
MORRISVILLE, N.C.--(BUSINESS WIRE)-- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on providing products to address conditions with significant unmet medical needs, today announced that it has regained compliance with the minimum bid price requirement of $1.00 per share for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). On February 23, 2018, Tenax effected a 1-for-20 reverse stock split of its outstanding common stock...
Tenax Therapeutics Announces New Scientific Publication of Preclinical...
MORRISVILLE, N.C.--(BUSINESS WIRE)-- Tenax Therapeutics, Inc. (Nasdaq: TENX) today announced the publication of a positive preclinical study of levosimendan conducted by Hansen et al in the March 1, 2018, issue of Pulmonary Circulation. The study was titled “Levosimendan improves cardiac function and myocardial efficiency in rats with right ventricular failure” and found that chronic administration of levosimendan improved right heart function. Dr. Hansen and colleagues assessed the effects of levosimendan in an experimental model of ...
Tenax Therapeutics Announces Reverse Stock Split
MORRISVILLE, N.C.--(BUSINESS WIRE)-- Tenax Therapeutics, Inc. (NASDAQ: TENX), a specialty pharmaceutical company focused on providing products to address conditions with significant unmet medical needs, today announced a reverse stock split of its shares of common stock at a ratio of 1-for-20. Beginning with the opening of trading on Monday, February 26, 2018, the Company’s common stock will continue to trade on the Nasdaq Capital Market ("Nasdaq") under the symbol "TENX," but will trade on a split-adjusted basis under a new CUSIP num...
World-Recognized Experts Join Tenax Therapeutics’ Scientific Advisor...
MORRISVILLE, N.C--(BUSINESS WIRE)-- Tenax Therapeutics, Inc. (NASDAQ: TENX) a leading specialty pharmaceutical company focused on providing products to address conditions with significant unmet medical needs, today announced the appointment of three internationally recognized medical experts in the fields of pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF) to its Scientific Advisory Board for the company’s planned Phase 2 clinical study in the use of levosimendan for patients with PH-HFpEF. ...
Tenax Therapeutics Announces Plan to Develop Levosimendan for a Pulmon...
MORRISVILLE, N.C.--(BUSINESS WIRE)-- Tenax Therapeutics, Inc. (NASDAQ: TENX) today announced plans to advance the development of levosimendan for the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF). PH-HFpEF is a common condition with a poor outcome (5 year survival less than 50%). Given that no therapies are approved to treat an estimated 1.5 million patients who suffer from this condition, it represents a disease with high unmet medical need. Tenax plans to initiate a Phas...
Tenax Therapeutics Provides Regulatory Update on Levosimendan
MORRISVILLE, N.C.--(BUSINESS WIRE)-- Tenax Therapeutics, Inc. (NASDAQ: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today provides a regulatory update following discussions with the U.S. Food and Drug Administration (FDA) and Health Canada regarding a regulatory path forward for levosimendan. In May 2017, the Company participated in a pre-NDA meeting with the FDA to discuss the possibility of submitting an NDA for levosimendan in two ...
Tenax Meets with FDA to Discuss Positive Mortality Data and Potential ...
MORRISVILLE, N.C.--(BUSINESS WIRE)-- Tenax Therapeutics, Inc. (NASDAQ: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today provided an update on its recent pre-NDA meeting with the FDA. Tenax met with the FDA on May 10, 2017 to review additional data analyses from the recently completed Phase 3 LEVO-CTS clinical study of levosimendan in cardiac surgery patients at risk of LCOS. The discussion with the FDA built on previously presented pr...
Tenax Therapeutics Announces Review of Strategic Alternatives and Busi...
MORRISVILLE, N.C.--(BUSINESS WIRE)-- Tenax Therapeutics, Inc. (NASDAQ: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today provided an update related to its business strategy, the clinical development of its product candidates and its management team: The Company’s Board of Directors is conducting a comprehensive review of strategic alternatives focused on maximizing stockholder value and has formed a strategic committee of ...
Tenax Therapeutics Announces Year-End 2016 Financial Results and Provi...
MORRISVILLE, N.C.--(BUSINESS WIRE)-- Tenax Therapeutics, Inc. (NASDAQ: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today announced financial results for the full year ended December 31, 2016 and provided a corporate update. “While we were disappointed that the LEVO-CTS trial did not meet its dual or quad primary endpoints, there are positive data in the results. Levosimendan demonstrated statistically significant reductions in clinical...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.